Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer
Crossref DOI link: https://doi.org/10.1007/s10637-015-0272-0
Published Online: 2015-07-21
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gustavsson, Bengt
Carlsson, Göran
Swartling, Torbjörn
Kurlberg, Göran
Derwinger, Kristoffer
Björkqvist, Hillevi
Odin, Elisabeth
Gibson, Fernando
Text and Data Mining valid from 2015-07-21
Version of Record valid from 2015-07-21
Article History
Received: 25 March 2015
Accepted: 7 July 2015
First Online: 21 July 2015